Motif Bio plc:
PDUFA date: Feb 13, 2019 for Antibiotic Iclaprim. Two Phase 3 trials in pts w acute bacterial skin and skin structure infections (ABSSSI) achieved primary and secondary endpoints. Compared to SoC (vancomycin), no observed nephrotox and a fixed dose. Potential other indications include HABP/VABP and S. aureus lung infections in CF (orphan).
125 Park Avenue
New York, NY 10017
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Stock Market Data
Market Data copyright © 2017 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by